METTL1 and hepatocellular carcinoma: Furthermore, Expression levels of METTL1 and WDR4 were found to be highly elevated in lenvatinib‐resistant HCC cells, suggesting that aberrant activation of the METTL1/WDR4‐mediated m7G pathway may underlie therapeutic resistance and that these enzymes could serve as biomarkers to predict lenvatinib efficacy.76